TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00962299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day by metered dose inhaler with spacer for 6 months
Study: NCT02029209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsule QD
Study: NCT02246842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-Gam® (human anti-D immunoglobulin)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhophylac® (human anti-D immunoglobulin)
Study: NCT00520507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive form of the treatment will be taken once daily at 6pm for 1 month.
Study: NCT01348295

Intervention type: OTHER
Intervention: Observation
Description: No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
Study: NCT02970643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
Study: NCT02484781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait analysis on a trendmill
Description: Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait analysis on a trendmill
Description: Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining
Study: NCT02390102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution 0.9%
Study: NCT01983033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drop It training session
Description: 8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: treatment as usual
Description: 12 weeks of no intervention other than treatment as usual
Study: NCT01644799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idelalisib
Description: oral
Study: NCT02970643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
Study: NCT01623622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-58
Description: once or more / week
Study: NCT01644799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: oral
Study: NCT00384748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TR intervention
Description: The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home messaging device.
Description: The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine VA care.
Study: NCT02787421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe-Rite Nasal Dilator Strip
Description: During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
Study: NCT02702388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib matching placebo
Description: Lenvatinib matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib matching placebo
Description: Lenvatinib matching placebo capsule.
Study: NCT04830111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback Application (Eureka iDestressor)
Description: heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
Study: NCT04092959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese square dancing group
Description: Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
Study: NCT03862105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health app tool - Twistle
Description: The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
Study: NCT02025985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.
Study: NCT04679311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High ACE Activity Fresh Frozen Plasma
Description: Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will be treated with normal saline 500 cc
Study: NCT04046770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug administration and Flushing procedure using Double-Chamber Syringe
Description: The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug administration and Flushing procedure using Classic Syringe
Description: To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
Study: NCT02025985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.
Study: NCT03369652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Conducted by the pharmacist and discussed with hospital physician
Study: NCT04072198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg every 2 weeks for 8 cycles followed by maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg every 2 weeks for 8 cycles followed by maintenance
Study: NCT04377230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic limb length of 60cm.
Description: Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliopancreatic limb length of 100cm.
Description: Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
Study: NCT03329898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: disposable balloon uterine stent
Description: the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: estradiol valerate tablets
Description: oral estradiol valerate tablets, which can promote endometrial growth after operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets
Description: oral estradiol valerate tablets, which can promote endometrial growth after operation.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: dydrogesterone Tablets
Description: oral dydrogesterone Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dydrogesterone Tablets
Description: oral dydrogesterone Tablets
Study: NCT01762150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg BID by oral until progressed;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
Study: NCT02579564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncorine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT04072198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/m2 every 2 weeks for 8 cycles
Study: NCT02579564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study: NCT02710448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
Study: NCT01665950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Study: NCT04536012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification and Social Incentives
Description: Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
Study: NCT01971775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonically activated Shears
Description: Dissection and lymphovascular sealing with Ultrasonically Activated Shears

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Monopolar Electrocautery
Description: Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
Study: NCT01356303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, docetaxel
Description: All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles.
Study: NCT03841058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: 80 mcg delivered SC by a pen
Study: NCT02088151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
Description: Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
Study: NCT00676182

Intervention type: OTHER
Intervention: Telerehabilitation
Description: Rehabilitation via computer assisted internet capabilities
Study: NCT04069325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simiaowan
Description: pills, 6g twice daily (BID), oral, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pills, 6g twice daily (BID), oral, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: febuxostat
Description: tablets, 40 mg once daily (QD), oral, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: tablets, 40 mg once daily (QD), oral, 12 weeks
Study: NCT03372330

Intervention type: DRUG
Intervention: Standard care for sepsis and PAD
Description: The standard medications care for the patient with PAD included antiplatelet agents.

Intervention type: DRUG
Intervention: Standard care for sepsis
Description: The standard care for the patient with sepsis.
Study: NCT04358172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Oral and Denture Guide' mobile application
Description: 'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
Study: NCT01631890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound assisted endoscopic glue injection
Description: N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endotherapy
Description: Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
Study: NCT03093116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005) capsules.
Study: NCT03323619

Intervention type: PROCEDURE
Intervention: anesthesia type
Description: No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
Study: NCT04072198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 every 2 weeks for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2 every 2 weeks for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoruracil
Description: 3200mg/m2 every 2 weeks for 8 cycles
Study: NCT00585208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: Ramelteon 8mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for ramelteon 8mg daily
Study: NCT01623622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-58
Description: once or more / week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once or more / week
Study: NCT01950988

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush reference

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush reference

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush reference

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure of the dental plaque
Study: NCT03841058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide
Description: 80 mcg delivered SC by a pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pen to deliver a SC dose of placebo
Study: NCT01637454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
Study: NCT01950988

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure of the dental plaque

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure of the dental plaque